AR075396A1 - Derivados de quinazolinas y composiciones farmaceuticas - Google Patents
Derivados de quinazolinas y composiciones farmaceuticasInfo
- Publication number
- AR075396A1 AR075396A1 ARP100100376A ARP100100376A AR075396A1 AR 075396 A1 AR075396 A1 AR 075396A1 AR P100100376 A ARP100100376 A AR P100100376A AR P100100376 A ARP100100376 A AR P100100376A AR 075396 A1 AR075396 A1 AR 075396A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- atoms
- atom
- replaced
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004429 atom Chemical group 0.000 abstract 6
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de amino carboxamida azaheterocíclica sustituida, su fabricacion y su uso para el tratamiento de enfermedades hiperproIiferativas como el cáncer. Reivindicacion 1: Un compuesto caracterizado porque responde a la Formula (1) y sales aceptables farmacéuticamente, solvatos o prodrogas del mismo, donde: X es N o C-R3, Y es NH, O se encuentra ausente, R1 es L1-R4-L2-R5-L3-R6, L1-R4-L2-R5 o L1-R4, R2', R2'' cada uno, en forma independiente entre si, son H, A Hal, OH, OA, SH, CN, NH2, NO2, NHA, NH-L1-Ar, NHCOA, NHCO-L1-Ar, NHSO2A, NHSO2-L1-Ar, NHCONHA o NHCONH-L1-Ar, L1-Ar, O-L1-Ar, L1-R4, L1, L3 cada uno, en forma independiente entre si son una union simple, alquileno no ramificado o ramificado con 1, 2, 3, 4 o 5 átomos de C el cual puede estar no sustituido, o estar mono- o disustituido con Hal, OH, CN, NH2, NH(LA), N(LA)2, NO2, COOH, N3, etenilo o etinilo, y/o monosustituidos con R4, y en el cual uno o dos grupos CH2 se pueden reemplazar con un átomo de O o S o con un grupo -NH-, -N(LA)-, -CONH-, -N(LA)COO-, -SO2- o -NHCO-, R3 es H, A, Hal, OH, COOH, SH, NH2, NO2 o CN, R4, R5, R6 cada uno, en forma independiente entre si, son Ar, o alquilo monocíclico con 3, 4, 5, 6 o 7 átomos del anillo, en el cual uno o dos grupos CH2 se pueden reemplazar con un átomo de O o S y/o con un grupo -NH-, -NA-, -CHA-, -CO-, CH=N o -CH=CH-, y/o en el cual el grupo conector CH se puede reemplazar con un átomo de N, y el cual puede estar mono o di-sustituido con Hal o LA, L2 es -NHCO-, -NHCOO-, -NHCONH-, -NHCONA-, -NHCOA-, -O-, -S-.,-NH-, -NHSO2-, -SO2NH-, -CONH-, -CONHCONH-, -NHCONHCO-, o -A-, Ar es un homo- o heterociclo aromático mono- o bicíclico con 0, 1, 2, 3 o 4 átomos de N, O y/o S y 5, 6, 7, 8, 9, o 10 átomos del esqueleto, que pueden estar no sustituidos o, en forma independiente entre si estar mono- di- o tri-sustituidos con Hal A, OH, SH, OA, NH2, NHA, NA2, NO2, CN, OCN, SCN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONHA, NHCONH2, NHSO2A, CHO, COA, SO2NH2, SO2A y/o SO2Hal, y en el cual un átomo de N del anillo puede estar sustituido con un átomo de O para formar un grupo N-oxido, y en el cual en el caso de un anillo aromático bicíclico uno de los dos anillos puede estar parcialmente saturado. A es alquilo lineal o cíclico no ramificado o ramificado con 1, 2, 3, 4, 5, 6, 7 o 8 átomos de C en el cual uno o dos grupos CH2 se pueden reemplazar con un átomo de O o S y/o con un grupo -NH-, -CO-, -NHCOO-, -NHCONH-, -N(LA)-, -CONH-, -NHCO- o -CH=CH-, y en el cual 1-3 átomos de H se pueden reemplazar con Hal, y en el cual uno o dos grupos CH3 se pueden reemplazar con OH, SH, NH2, NH(LA), N(LA)2, NHCOOH, NHCONH2 o CN, LA es alquilo lineal no ramificado o ramificado con 1, 2, 3 o 4 átomos de C, Hal es F, Cl, Br o I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20735409P | 2009-02-11 | 2009-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075396A1 true AR075396A1 (es) | 2011-03-30 |
Family
ID=42199208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100376A AR075396A1 (es) | 2009-02-11 | 2010-02-11 | Derivados de quinazolinas y composiciones farmaceuticas |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8637532B2 (es) |
| EP (1) | EP2396307B1 (es) |
| JP (1) | JP5642714B2 (es) |
| KR (1) | KR101699991B1 (es) |
| CN (1) | CN102317269B (es) |
| AR (1) | AR075396A1 (es) |
| AU (1) | AU2010214095B2 (es) |
| BR (1) | BRPI1008325A2 (es) |
| CA (1) | CA2751886C (es) |
| CL (1) | CL2011001967A1 (es) |
| DK (1) | DK2396307T3 (es) |
| EA (1) | EA020731B1 (es) |
| ES (1) | ES2527940T3 (es) |
| HR (1) | HRP20141239T1 (es) |
| IL (1) | IL214412A0 (es) |
| MX (1) | MX338354B (es) |
| MY (1) | MY160468A (es) |
| NZ (1) | NZ595087A (es) |
| PL (1) | PL2396307T3 (es) |
| PT (1) | PT2396307E (es) |
| SG (1) | SG173473A1 (es) |
| SI (1) | SI2396307T1 (es) |
| UA (1) | UA107188C2 (es) |
| WO (1) | WO2010093419A1 (es) |
| ZA (1) | ZA201106624B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA110113C2 (xx) * | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| BR112013002212A2 (pt) * | 2010-07-29 | 2017-09-26 | Merck Patent Gmbh | carboxamidas aza-heterocíclicas de aminas cíclicas |
| WO2012069146A1 (en) * | 2010-11-24 | 2012-05-31 | Merck Patent Gmbh | Quinazoline carboxamide azetidines |
| LT2755965T (lt) | 2011-09-12 | 2017-11-10 | Merck Patent Gmbh | Naujieji imidazolo aminai kaip kinazės aktyvumo moduliatoriai |
| BR112014005468A2 (pt) | 2011-09-12 | 2017-03-21 | Merck Patent Gmbh | derivados de aminopiridina para uso como moduladores de atividade quinase |
| EP2794571B1 (en) * | 2011-12-22 | 2016-11-02 | Merck Patent GmbH | Novel heterocyclic carboxamides as modulators of kinase activity |
| ES2656096T3 (es) | 2012-11-16 | 2018-02-23 | Merck Patent Gmbh | Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa |
| AU2013344552B2 (en) | 2012-11-16 | 2018-03-15 | Xiaoling Chen | Novel heterocyclic derivatives as modulators of kinase activity |
| EP2925747B1 (en) * | 2012-11-29 | 2020-06-24 | Merck Patent GmbH | Azaquinazoline carboxamide derivatives |
| CN104968200B (zh) | 2013-02-01 | 2018-03-06 | 维尔斯达医疗公司 | 具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物 |
| KR20150124957A (ko) | 2013-03-11 | 2015-11-06 | 메르크 파텐트 게엠베하 | 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체 |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| KR102410696B1 (ko) | 2014-04-03 | 2022-06-17 | 메르크 파텐트 게엠베하 | 암 치료법의 조합 |
| CN104292170B (zh) * | 2014-09-22 | 2016-06-29 | 广西师范大学 | 具有抗肿瘤作用的喹唑啉-芳基脲衍生物及其应用 |
| CA2965336A1 (en) * | 2014-10-22 | 2016-04-28 | The Board Of Regents Of The University Of Texas System | Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| FR3066761B1 (fr) | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
| JP2020526495A (ja) * | 2017-06-30 | 2020-08-31 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ヘテロクロマチン遺伝子抑制阻害薬 |
| CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
| TWI853814B (zh) * | 2018-05-31 | 2024-09-01 | 南韓商Ｃ＆Ｃ新藥研究所 | 雜環衍生物及其用途 |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| CN109369634B (zh) * | 2018-12-19 | 2021-07-27 | 陕西国际商贸学院 | 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途 |
| RU2723481C1 (ru) * | 2019-10-03 | 2020-06-11 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ УНИТАРНОЕ ПРЕДПРИЯТИЕ "ИНСТИТУТ ХИМИЧЕСКИХ РЕАКТИВОВ И ОСОБО ЧИСТЫХ ХИМИЧЕСКИХ ВЕЩЕСТВ НАЦИОНАЛЬНОГО ИССЛЕДОВАТЕЛЬСКОГО ЦЕНТРА "КУРЧАТОВСКИЙ ИНСТИТУТ" (НИЦ "Курчатовский институт - ИРЕА) | 4-[метил 4-(аминометил)циклогексанкарбоксилат]хиназолин и способ его получения |
| HRP20251479T1 (hr) | 2019-11-01 | 2026-01-02 | Syngenta Crop Protection Ag | Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi |
| CN112778217B (zh) * | 2019-11-08 | 2024-01-26 | 沈阳化工研究院有限公司 | 一种喹唑啉类化合物及其应用 |
| EP4243819A1 (en) | 2020-11-16 | 2023-09-20 | Merck Patent GmbH | Kinase inhibitor combinations for cancer treatment |
| AU2022299145A1 (en) | 2021-06-24 | 2023-12-07 | Syngenta Crop Protection Ag | 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides |
| TW202345806A (zh) | 2022-03-31 | 2023-12-01 | 美商艾伯維有限公司 | 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑 |
| KR20250002409A (ko) * | 2022-04-11 | 2025-01-07 | 메르크 파텐트 게엠베하 | Hpk1 억제제로서의 피리도[3,2-d]피리미딘 |
| CN119421880A (zh) | 2022-06-21 | 2025-02-11 | 先正达农作物保护股份公司 | 杀有害生物活性的稠合二环杂芳香族化合物 |
| CN115521474B (zh) * | 2022-09-30 | 2023-08-22 | 陕西科技大学 | 一种基于五重互穿氢键有机框架材料及其制备方法和应用 |
| WO2025228828A1 (en) * | 2024-04-29 | 2025-11-06 | Merck Patent Gmbh | Carboxamide compounds for the treatment and prevention of viral diseases |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0025705B1 (en) * | 1979-09-14 | 1983-06-22 | Development Finance Corporation Of New Zealand | Compounds having antitumour properties, process for their preparation, these compounds for use as antitumour agents and pharmaceutical compositions containing them |
| GB8804445D0 (en) * | 1988-02-25 | 1988-03-23 | Smithkline Beckman Intercredit | Compounds |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| PL354323A1 (en) * | 1999-09-21 | 2004-01-12 | Astrazeneca Ab | Quinazoline derivatives and their use as pharmaceuticals |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP1277738B1 (en) * | 2000-04-27 | 2011-03-30 | Astellas Pharma Inc. | Condensed heteroaryl derivatives |
| ES2305081T3 (es) * | 2000-06-28 | 2008-11-01 | Astrazeneca Ab | Derivados de quinozolina sustituidos y su uso como inhibidores. |
| MXPA04006260A (es) * | 2001-12-24 | 2005-03-31 | Astrazeneca Ab | Derivados de quinazolina sustituidos como inhibidores de cinasas aurora. |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| AU2004278413B2 (en) | 2003-09-30 | 2008-07-31 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AU2004283751B2 (en) | 2003-10-24 | 2011-05-19 | Exelixis, Inc. | p70S6 kinase modulators and method of use |
| RU2006121646A (ru) | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
| AU2004296868B2 (en) | 2003-12-09 | 2010-11-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods for suppressing an immune response or treating a proliferative disorder |
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| US7994172B2 (en) | 2004-12-28 | 2011-08-09 | Exelixis, Inc. | [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP2008546751A (ja) | 2005-06-22 | 2008-12-25 | アステックス・セラピューティクス・リミテッド | 医薬組成物 |
| EP1925941B1 (en) * | 2005-08-01 | 2012-11-28 | Eisai R&D Management Co., Ltd. | Method for prediction of the efficacy of vascularization inhibitor |
| TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
| EP2137177B1 (en) * | 2007-04-05 | 2014-05-07 | Amgen, Inc | Aurora kinase modulators and method of use |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| US7829574B2 (en) * | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
-
2010
- 2010-02-04 PL PL10705453T patent/PL2396307T3/pl unknown
- 2010-02-04 MX MX2011008395A patent/MX338354B/es active IP Right Grant
- 2010-02-04 ES ES10705453.8T patent/ES2527940T3/es active Active
- 2010-02-04 KR KR1020117021335A patent/KR101699991B1/ko active Active
- 2010-02-04 JP JP2011550122A patent/JP5642714B2/ja active Active
- 2010-02-04 CA CA2751886A patent/CA2751886C/en active Active
- 2010-02-04 EP EP10705453.8A patent/EP2396307B1/en active Active
- 2010-02-04 MY MYPI2011003710A patent/MY160468A/en unknown
- 2010-02-04 EA EA201101182A patent/EA020731B1/ru not_active IP Right Cessation
- 2010-02-04 UA UAA201110411A patent/UA107188C2/ru unknown
- 2010-02-04 DK DK10705453.8T patent/DK2396307T3/en active
- 2010-02-04 SG SG2011055001A patent/SG173473A1/en unknown
- 2010-02-04 US US13/148,903 patent/US8637532B2/en active Active
- 2010-02-04 SI SI201030849T patent/SI2396307T1/sl unknown
- 2010-02-04 CN CN201080007165.1A patent/CN102317269B/zh active Active
- 2010-02-04 WO PCT/US2010/000313 patent/WO2010093419A1/en not_active Ceased
- 2010-02-04 HR HRP20141239AT patent/HRP20141239T1/hr unknown
- 2010-02-04 BR BRPI1008325-1A patent/BRPI1008325A2/pt not_active IP Right Cessation
- 2010-02-04 NZ NZ595087A patent/NZ595087A/xx unknown
- 2010-02-04 AU AU2010214095A patent/AU2010214095B2/en active Active
- 2010-02-04 PT PT107054538T patent/PT2396307E/pt unknown
- 2010-02-11 AR ARP100100376A patent/AR075396A1/es not_active Application Discontinuation
-
2011
- 2011-08-02 IL IL214412A patent/IL214412A0/en active IP Right Grant
- 2011-08-11 CL CL2011001967A patent/CL2011001967A1/es unknown
- 2011-09-09 ZA ZA2011/06624A patent/ZA201106624B/en unknown
-
2013
- 2013-12-13 US US14/105,974 patent/US9040560B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075396A1 (es) | Derivados de quinazolinas y composiciones farmaceuticas | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| EA200870423A1 (ru) | Производные триазолпиразинов, применимые в качестве противораковых агентов | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| UY30437A1 (es) | Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c | |
| UY30392A1 (es) | Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c | |
| PE20140604A1 (es) | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| ECSP077648A (es) | Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
| AR082414A1 (es) | Carboxamidas azaheterociclicas biciclicas utiles para tratar enfermedades hiperproliferativas e inflamatorias, composiciones farmaceuticas que las contienen y procedimiento para prepararlas | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| ECSP077649A (es) | Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| CY1117792T1 (el) | Ανταγωνιστες toy trpv4 | |
| UY32490A (es) | Inhibidores de beta-secretasa | |
| UY30391A1 (es) | Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c | |
| AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
| EA201391337A1 (ru) | Ингибиторы hsp90 | |
| EA201170456A1 (ru) | Синергические комбинации макроциклического ингибитора вируса гепатита с и нуклеозида | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| EA201690230A1 (ru) | Соединения триазолона и их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FC | Refusal |